Pharsight

Rybelsus generic

Rybelsus is an anti-diabetic drug owned by Novo and was first authorized for market use on 20 September, 2019. The drug contains semaglutide as its active ingredient and comes in an oral tablet dosage form. Rybelsus holds a total of 11 drug patents, none of which have as yet expired.

When will Rybelsus generic be available?

The prospects for the release of Rybelsus generic are currently anticipated post 02 May, 2034, an estimate based on the expiry of its last patent (US10278923) titled 'Oral dosing of GLP-1 compounds'.

Rybelsus uses

Rybelsus is used as a method of treating type 2 diabetes mellitus. Its active ingredient, semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, which enhances the secretion of insulin hormone that reduces blood sugar levels.

Rybelsus patent expiration

Rybelsus holds a total of 11 drug patents, primarily concerning its GLP-1 compound and its solid composition combination with a salt of N-(8-(2-hydroxybenzoyl) amino). The last Rybelsus patent is set to expire on 02 May, 2034, paving the way for its generic versions; below is the detail of the patent:

EPO Oppostions filed on Rybelsus

Litigations filed on Rybelsus

Rybelsus dosage

Want to ask something?